ERBB2 and neoplasm: Curative-intent radical surgery remains the therapeutic cornerstone, while adjuvant systemic therapies guided by molecular biomarkers – including HER2 overexpression, mismatch repair (MMR) status, NTRK gene fusions, and tumor mutational burden – demonstrate potential to prolong PFS and optimize oncologic outcomes.